KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Inventory (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Change in Inventory for 16 consecutive years, with -$18.8 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory fell 343.09% to -$18.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.6 million through Dec 2025, down 103.79% year-over-year, with the annual reading at -$2.6 million for FY2025, 103.79% down from the prior year.
  • Change in Inventory for Q4 2025 was -$18.8 million at Halozyme Therapeutics, down from $1.1 million in the prior quarter.
  • The five-year high for Change in Inventory was $40.2 million in Q1 2024, with the low at -$18.8 million in Q4 2025.
  • Average Change in Inventory over 5 years is $5.1 million, with a median of $843500.0 recorded in 2025.
  • The sharpest move saw Change in Inventory soared 17717.44% in 2022, then plummeted 343.09% in 2025.
  • Over 5 years, Change in Inventory stood at -$2.2 million in 2021, then surged by 232.72% to $2.9 million in 2022, then plummeted by 149.88% to -$1.5 million in 2023, then skyrocketed by 625.94% to $7.7 million in 2024, then tumbled by 343.09% to -$18.8 million in 2025.
  • According to Business Quant data, Change in Inventory over the past three periods came in at -$18.8 million, $1.1 million, and $14.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.